Support

  • Where to buy
  • Choose your location

Image Gallery

NEW

Transcriptional Cyclin-Dependent Kinase

  • Publish: 2019/07/04
Kinase inhibitors target CDKs in the basal transcriptional machinery could preferentially affect highly proliferative tumor cells.
TOP
  • Frequency of EGFR Mutations in EGFR-mutated Non-Small Cell Lung Cancer

    EGFR mutations occur within exons 18–21 encoding a portion of the EGFR kinase domain. These mutations affect the kinase activity of EGFR, leading to downstream pro-survival signaling pathways.

    Publish: 2019/06/12

  • Single-Cell Molecular Profiling for Precision Cancer Research

    Single-Cell Applications

    Publish: 2019/06/12

  • Systemic Communication in Tumor Microenvironment

    Together with chemokines, the tumour microenvironment that incorporates tumour cell characterization, immune cell profiling and tumor vasculature remodeling provides a complete picture to monitor tumor progression.

    Publish: 2019/06/12

  • Mechanistic Overview of CARs targeting cancer cell

    CARs (1) First Generation: Containing only 1 single signaling domain derived from CD3ζ(2)Developed to contain a co-stimulatory domain, 2 signaling domains in total: represented here by CD28 and CD3ζ (3)Incorporates additional co-stimulatory domains, 3 or 4 signaling domains in total: Image depicted a third generation CARs by CD28, CD137 and CD3ζ

    Publish: 2019/06/13

  • Microenvironment Signaling of Chronic Lymphatic Leukemia

    1. Proliferation centers are formed in bone marrow and secondary lymphoid tissue where CLL cells interact with mesenchymal-derived stromal cells (MSC), T cells and nurse-like cells (NLC) through adhesion molecules and chemokine receptors, promoting CLL survival, proliferation, and migration. 2. MSC creates tissue niches and protects CLL cells from apoptosis. In addition, CLL cell survival can also be promoted by WNT factors secreted from MSC. 3. NLC/CLL crosstalks active nuclear factor-κB (NF-κB) and enhance CLL proliferation before exiting lymphoid tissue into the blood vessels. 4. Through CCL12/22 chemokines, T cells are recruited into the tissue microenvironment where activated T cells provide CLL cells with proliferative and survival signals.

    Publish: 2019/06/13

  • Diagnostic Exosomal Markers in Biofluids

    Exosomes biomarkers in diseases.

    Publish: 2019/06/10

  • Distinct Metabolic Configurations

    Alterations in generation and utilization of metabolic energy support different immune cell functions.

    Publish: 2019/06/12

  • BRAF Introduction and Treatment for BRAF-Mutated Cancer

    Inhibition of RAF alone or in combination with MEK is effective in slowing the progression of BRAF V600-mutanted cancers. However, tumors adapt to therapy and drug effectiveness is limited by resistance which is associated with RAS mutations, BRAF V600E splice variants, BRAF amplification and MEK mutations. Additionally, stromal cells in the tumor microenvironment release hepatocyte growth factor/cytokines could promote resistance to RAF inhibitors and reactivate ERK signaling pathway by activating PI3K signaling.

    Publish: 2019/06/12

ALL
  • Action of Intrabodies and Antibodies Targeting HTT

    Anti-HTT scFv and Anti-mHTT antibody.

    Publish: 2019/06/10

  • Activity of EGFR-Directed Therapies

    Heterogeneous EGFR-mutated lung adenocarcinomas undergo clonal selection upon treatment of EGFR TKIs. There are sequences of changes in clonal predominance upon treatment exposure/adaptation to 1st & 2nd and subsequently 3rd generation EGFR TKIs.

    Publish: 2019/06/12

  • Advantages and disadvantages of Preclinical Models

    Advantages and disadvantages of Patient Derived Xenografts (PDx), Cancer Cell Line-Derived Xenografts (CDx), Genetically Engineered Mouse (GEM) Models, Genetically Engineered Mouse-Derived Allografts (GDA) and CTC-Derived PDx and GDA .

    Publish: 2019/06/12

  • Advantages of NGS

    NGS overcomes limitations of traditional Sanger sequencing. NGS enables the simultaneous screening of multiple genes in multiple samples, and can widely be used in genetic research to detect numerous genetic variants such as single nucleotide variants (SNVs), multiple nucleotide variants (MNVs), insertions and deletions (indels) and copy number variants (CNVs).

    Publish: 2019/06/10

  • Advantages of rabbit monoclonal antibodies

    Monoclonal antibodies (mAbs), which have been essential tools for research use or clinical therapeutics, are often mouse origin. However the mouse system is limited by a small spleen and are usually inbred which leads to a less diversity of immune response. The rabbit has robust immune system and bigger spleen to generate antibodies with high affinity, high specificity and broad immunogenicity. Further, the simpler structure of rabbit immunoglobin makes it easy for cloning, engineering and humanizing of the antibody which benefits therapeutic antibody development. Here we compare differences between mouse and rabbit antibody and outline current approaches to rabbit monoclonal antibody generation.

    Publish: 2019/06/13

  • Alpha-Synuclein Induced NLRP3 Inflammasome

    The microglia will recognize, uptake and phagocyte the different type of alpha-synuclein (monomeric, oligomeric, or fibrillary) changing during neuronal the progress of neurological diseases. Alpha-synuclein initiates and interacts with membrane receptors leading to assembly of the NLRP3 inflammasome.

    Publish: 2019/06/11

  • Applications of NGS

    Next-generation sequencing (NGS) has become an important technology, which provides deeper insights into human genome. With its speed, accuracy and affordability, NGS enables a wide variety of applications including whole genome sequencing, ChIP sequencing, exome sequencing and transcriptome sequencing.

    Publish: 2019/06/10

  • AR Phosphorylation

    AR activity can be promoted or inhibited by AR phosphorylation which can affect its activity via influencing AR translocation, AR-binding DNA, AR stability.

    Publish: 2019/06/10

  • AR Signaling Axis

    Androgen-dependent and independent mechanisms of disease progression

    Publish: 2019/06/10

  • AR Splice Variant

    Androgen receptor (AR) is a member of the steroid receptor transcription factor family. In prostate cancer, increased levels of androgens in the tumor cells promote (1) AR signaling associated with cell-cycle regulation, growth, and survival, and (2) the expression of oncogenic fusion genes (including PSA, TMPRSS2, and hK2). Alterations in AR transcripts disrupt the open reading frame leading to the expression of truncated proteins that are not androgen dependent. AR-V7 is one of the splice variants of AR lacking the C-terminal LBD, but being constitutively active as a transcription factor and capable of promoting activation of target genes.

    Publish: 2019/05/29

  • BRAF Introduction and Treatment for BRAF-Mutated Cancer

    Inhibition of RAF alone or in combination with MEK is effective in slowing the progression of BRAF V600-mutanted cancers. However, tumors adapt to therapy and drug effectiveness is limited by resistance which is associated with RAS mutations, BRAF V600E splice variants, BRAF amplification and MEK mutations. Additionally, stromal cells in the tumor microenvironment release hepatocyte growth factor/cytokines could promote resistance to RAF inhibitors and reactivate ERK signaling pathway by activating PI3K signaling.

    Publish: 2019/06/12

  • Breast Tumor Subtypes

    Breast Tumor Subtypes

    Publish: 2019/06/12

  • Cancer Biomarkers CSV vs EpCAM

    Exclusive CSV Antibody and Circulating Rare Cell Enrichment & Retrieval System.

    Publish: 2019/06/12

  • Cancer Immunity Cycle

    1. Release of cancer cell antigens 2. Cancer antigen presentation 3. Priming and activation of T Cells 4. Trafficking of T cells to tumors 5. Infiltration of T cells into tumors 6. Recognition of cancer cells by T cells 7. Killing of cancer cells

    Publish: 2019/06/13

  • Chemokine Functions in the Tumor Microenvironment

    Chemokine Induced Pro-tumour and Anti-tumor effects

    Publish: 2019/06/12

  • Chimeric Antigen Receptor (CAR) T Cell Therapy

    Individualized CAR T therapy uses patient’s own immune system to fight cancers. A patient’s T cells are extracted and reprogrammed to express CARs which can recognize particular tumor-associated antigens and kill cancer cells.

    Publish: 2019/06/10

  • Clinical Status of Transcription-Associated Kinase Inhibitors

    Clinical Status and Indication of Transcription-Associated Kinase Inhibitors

    Publish: 2019/07/03

  • Clinical Utilities of NGS in Oncology NGS in Oncology

    NGS has been applied to identify actionable mutations and personalize treatments to target genetic variants for cancer patients. Clinical results have showed that patients treated with sequencing-matched therapies had improved overall response rate (ORR), time to treatment failure (TTF), overall survival (OS), progression free survival (PFS) and tumor response rate (TRR).

    Publish: 2019/06/10

  • Comparison of Preclinical Models

    Comparison between Cancer Cell Line-Derived Xenografts (CDx), Patient cancer-Derived Xenografts (PDx), Genetically Engineered Mouse (GEM) and GEM-Derived Allografts (GDA).

    Publish: 2019/06/12

  • Comparison of rabbit mAb generation methods

    We compare differences between mouse and rabbit antibody and outline current approaches to rabbit monoclonal antibody generation.

    Publish: 2019/06/13

  • Cytoskeleton Compositions

    Actin Crosslink, Myosin and Actin Filament and Microtubule Transport System

    Publish: 2019/06/13

  • Diagnostic Exosomal Markers in Biofluids

    Exosomes biomarkers in diseases.

    Publish: 2019/06/10

  • Distinct Metabolic Configurations

    Alterations in generation and utilization of metabolic energy support different immune cell functions.

    Publish: 2019/06/12

  • DNA Methylation-based Diagnostic Test

    Epigenetic profiling to classify cancer types upon the microarray DNA methylation signatures with a reported specificity of 99.6% (95% CI 99.5–99.7), sensitivity of 97.7% (96.1–99.2), positive predictive value of 88.6% (85.8–91.3), and negative predictive value of 99.9% (99.9–100.0) in the validation set of 7691 known tumor samples. Methylation profiling also predicted an origin cancer site of patients (87%) with cancer with unknown primary origin.

    Publish: 2019/06/12

  • Effective CTC Isolation and Clinical Applications of Circulating Tumor Cells

    (1) Immunomagnetic Methods Positive Enrichment, (2) Immunomagnetic Methods Negative Enrichment and (3)Microfluidic Technologies Positive Enrichment.

    Publish: 2019/06/12

  • Epigenetic Drugs in Cancer

    Histone deacetylases (HDACs), Sirtuins, Histone demethylases (HDMs), Histone acetyltransferases (HATs), Histone methyltransferases (HMTs), Methyl-CpG-binding proteins, DNA methyltransferases (DNMTs).

    Publish: 2019/06/12

  • Epigenetic Gene Regulation

    Histone and DNA Modifications

    Publish: 2019/06/13

  • Epithelial-Mesenchymal Transition

    Mechanistic Overview of EMT mechanism from extracellular stimuli

    Publish: 2019/06/13

  • Exosome

    Exosome Formation and Composition

    Publish: 2019/06/10

  • Exosomes as drug carriers

    Engineered exosomes targeting oncogenic KRAS restrain tumor growth and increase overall survival.

    Publish: 2019/06/10

  • FDA-Approved Drugs Targeting HER2

    Mechanisms of FDA-Approved Drugs Targeting HER2 and their indications.

    Publish: 2019/06/12

  • FDA-Approved NGS for Clinical Diagnostics

    FDA-Approved NGS for Clinical Diagnostics in Companion Diagnostic and Complementary Diagnostic.

    Publish: 2019/06/10

  • FISH Applications

    Detecting genetic alternations or monitoring the progression of an aberration in helping the diagnosis or suggesting prognostic outcomes.

    Publish: 2019/06/10

  • FISH Clinical Applications in Detecting Genetic Alternation

    FISH Clinical Applications in Monitoring and Treatment

    Publish: 2019/06/10

  • FISH Clinical Applications in Detecting Genetic Alternation

    FISH Clinical Applications in Diagnosis

    Publish: 2019/06/10

  • FISH Probes Approved by the FDA Center

    FISH Probes Approved by the FDA Center for Devices and Radiological Health

    Publish: 2019/06/12

  • FISH Probes vs mutaFISH™ Probes

    Advantages and Applications of FISH Probes and mutaFISH™ Probes

    Publish: 2019/06/12

  • Frequency of BRAF V600E Point Mutation among Cancers Harbor BRAF-Mutations

    BRAF mutations are present in approximately 8% of human tumors, particularly the most frequent BRAF V600E point mutation in those with melanoma, colorectal, thyroid, ovarian, or lung cancers.

    Publish: 2019/06/12

  • Frequency of EGFR Mutations in EGFR-mutated Non-Small Cell Lung Cancer

    EGFR mutations occur within exons 18–21 encoding a portion of the EGFR kinase domain. These mutations affect the kinase activity of EGFR, leading to downstream pro-survival signaling pathways.

    Publish: 2019/06/12

  • Gene Expression Associated with Increased HSF1 Level in Cancer

    Gene Up-regulation and Down-regulation Associated with Increased HSF1 Level in Cancer.

    Publish: 2019/06/10

  • HER2 Signaling Pathway

    HER2, EGFR, HER3, and IGF-1R dimerized with the HER2 receptor induce activation of PI3K/AKT and MAPK/MEK signaling pathways and receive signals to regulate downstream cascade that promotes the active transcription of genes involved in proliferation, angiogenesis, cell survival, and metastasis.

    Publish: 2019/06/12

  • HER2 Testing

    HER2 Testing (1) IHC: Immunohistochemistry (IHC) measures the levels of HER2 protein on the surface of the cancer cells. (2) ISH: In-situ hybridization (ISH) measures the copies of the HER2 gene within 1 cancer cell

    Publish: 2019/06/12

  • HSF1 Activation Cycle

    Inactive monomeric heat shock factor 1 (HSF1) exists predominantly in the cytoplasm and remains repressed by complex with regulatory proteins of HSF1 its own transcriptional targets of heat-shock protein (HSP) and cytosolic chaperonin TCP1 ring complex (TRiC). Upon a wide range of stress conditions, HSF1 is activated to undergo trimerization, nuclear translocation, and post-translational modifications (PTMs) including phosphorylation, acetylation, and sumoylation, converted into a DNA-binding-competent, active homotrimer. HSF1 is then modified by different inhibitory PTMs to cause DNA dissociation, HSF1 inactivation, and HSF1 recycling/degradation and maintained in a negative-feedback mechanism.

    Publish: 2019/06/10

  • HSF1 Signaling Pathway

    HSF1 in cancer-associated fibroblasts (CAFs) drives the activation of expression and leads to the secretion of transforming growth factor-β (TGF-β) and stromal cell-derived factor 1 (SDF1) to enhance cancer proliferation, angiogenesis, and metastasis.

    Publish: 2019/06/10

  • HTT-Targeted Therapeutic Approaches

    HTT silencing modalities have been evaluating in many studies including antisense oligonucleotides (ASOs) that activate RNaseH-dependent degradation; agents that harness the endogenous RNA interference (RNAi) machinery; and suppressing Zinc-finger complexes etc.

    Publish: 2019/06/10

  • IDH1/2 Mutations

    IDH1 in the cytoplasm and IDH2 in the mitochondria catalyze the reversible oxidative decarboxylation of isocitrate to α-KG with concomitant reduction of NADP+ to NADPH. The heterozygous somatic mutations at R132 (IDH1) and at R172 (IDH2) in the catalytically active sites confer a gain-of-function neomorphic enzymatic activity, which can both produce the oncometabolite 2-HG.The resulting elevated 2-HG competitively inhibits α-KG-dependent enzymes, causing cellular alterations in cellular metabolism, epigenetic regulation, redox states, and DNA repair, all of which may contribute to tumorigenesis.

    Publish: 2019/06/10

  • Kinase Targets in Oncology

    Kinases have been considered as targets of cancer treatment for years. While several studies discovered the therapeutic potential of receptor tyrosine kinase (RTK) inhibition, research has recently put a spotlight on kinases that influence basal cellular process in cancer. Cyclin-dependent kinase (CDK) is one of the new areas that has been focused. As transcription-associated kinases, CDKs represent opportunities for the development of treatments for transcriptional-addicted cancers.

    Publish: 2019/07/03

  • Mammalian Autophagy (Macroautophagy) Pathway

    (1) Autophagy induction & initiation (2) Fusion & degradation (2) Elongation nucleation

    Publish: 2019/06/10

  • Mechanisms of Acquired Resistance to EGFR TKI Therapy

    (1)EGFR-Dependent Secondary Mutation, (2)Activation of Bypass Pathways, (3)Phenotypic Change and (4)Immune Escape

    Publish: 2019/06/12

  • Mechanisms of IDH Mutations Associated to Tumorigenesis

    Isocitrate dehydrogenases 1 (IDH1) and IDH2 mutations have been identified in >80% of low-grade gliomas and secondary glioblastomas (GBM), ~60% of chondrosarcomas, ~20% of intrahepatic cholangiocarcinomas (ICC), and as well as in ~10% of acute myeloid leukemia (AML) cases. IDH1/2 mutations exhibiting a significant alteration in cellular metabolism, epigenetic regulation, redox states, and DNA repair are involved in the development and progression of early events in tumorigenesis.

    Publish: 2019/06/10

  • Mechanistic Overview of CARs targeting cancer cell

    CARs (1) First Generation: Containing only 1 single signaling domain derived from CD3ζ(2)Developed to contain a co-stimulatory domain, 2 signaling domains in total: represented here by CD28 and CD3ζ (3)Incorporates additional co-stimulatory domains, 3 or 4 signaling domains in total: Image depicted a third generation CARs by CD28, CD137 and CD3ζ

    Publish: 2019/06/13

  • Methods for rabbit mAb generation

    Methods for rabbit mAb generation: (1)Hybridoma (2)Phage display (3)Single cell cloning

    Publish: 2019/06/13

  • Microenvironment Signaling of Chronic Lymphatic Leukemia

    1. Proliferation centers are formed in bone marrow and secondary lymphoid tissue where CLL cells interact with mesenchymal-derived stromal cells (MSC), T cells and nurse-like cells (NLC) through adhesion molecules and chemokine receptors, promoting CLL survival, proliferation, and migration. 2. MSC creates tissue niches and protects CLL cells from apoptosis. In addition, CLL cell survival can also be promoted by WNT factors secreted from MSC. 3. NLC/CLL crosstalks active nuclear factor-κB (NF-κB) and enhance CLL proliferation before exiting lymphoid tissue into the blood vessels. 4. Through CCL12/22 chemokines, T cells are recruited into the tissue microenvironment where activated T cells provide CLL cells with proliferative and survival signals.

    Publish: 2019/06/13

  • Microglia Activities in β-amyloid Pathology

    In an early stage, microglia can clear β-amyloid peptides via micropinocytosis, uptake of ApoE-associated β-amyloid, or phagocytosis of insoluble β-amyloid plaque. Microglia also help corral toxic β-amyloid deposits in plaques to minimize damage to the adjacent neuropil. In a later stage, microglia can secrete factors to activate astrocytes participating in amyloid-dependent synapse loss.

    Publish: 2019/06/13

  • Microglia Function Transition Associated with Neurodegeneration

    Resting Microglia Transform into Degeneration-Associated Microglia.

    Publish: 2019/06/13

  • mutaFISH™ Probes

    Abnova has integrated padlock probe and rolling circle amplification (RCA) for in situ, single cell, single molecule, DNA and RNA mutation detection at single nucleotide resolution. Abnova provides a growing portfolio of off-the-shelf, validated mutaFISH™ probes and accessory reagents to interrogate cellular heterogeneity at the single cell and single molecule levels and address the unmet needs in the research and clinical settings.

    Publish: 2019/06/12

  • Neurodegenerative Disorder

    Mitochondria Implicated Neurodegenerative Disorder Pathways

    Publish: 2019/06/13

  • NLRP3 Inflammasome Inhibitors in CNS diseases

    NLRP3 Inflammasome Inhibitors in CNS diseases and their Potential mechanisms.

    Publish: 2019/06/12

  • Oncogenic Alterations

    Mutations can occur in the genomes of cells and contribute towards oncogenesis.

    Publish: 2019/06/10

  • Ongoing Clinical Trials Involving Exosomes

    Ongoing Clinical Trials Involving Exosomes

    Publish: 2019/06/10

  • Pathogenic Mechanism in Huntington's Disease

    Full-length mutant huntingtin (mHTT) can be further processed to generate smaller fragments and the amino-terminal HTT exon 1 protein fragments are formed by aberrant splicing. Fragments can undergo self-association, oligomerization, and aggregation in the nucleus and cytoplasm, leading to the formation of inclusions that cause numerous pathogenic mechanisms, including synaptic dysregulation, mitochondrial toxicity, energy imbalance, and impaired axonal transport in Huntington's disease.

    Publish: 2019/06/10

  • Personal Regulomes in Human Cancer

    In heterogeneous cutaneous T cell lymphoma (CTCL), chromatin signatures distinguish leukemic, host and normal CD4+ T cells; their clinical response to HDAC inhibitors, romidepsin, is associates with distinct CTCL DNA accessibility.

    Publish: 2019/06/12

  • Plasticity of Tumor & Clonal Heterogeneity

    Understanding of the heterogeneous nature of a tumor that can influence tumor progression and drug resistance.

    Publish: 2019/06/12

  • Precision Cancer Medicine Tools: Circulating Tumor Cell Detection

    Unlocking the Potential of Personalized Medicine through Liquid Biopsy Technology. Companion Diagnostics Minimizing Sides Effects of Drug. Clues to Treatment in Blood. The Diagnostic Value of Circulating Tumor Cells Detection.

    Publish: 2019/06/12

  • Preclinical Mouse Tumor Model Studies Published in 2016

    Preclinical Mouse Tumor Model Studies in Different Cancers.

    Publish: 2019/06/12

  • Preclinical Mouse Tumor Models in Cancer Research

    PDx: Patient Derived Xenografts, CTC-PDx:CTC-Derived PDx, CDx:Cancer Cell Line-Derived Xenografts, GEM:Genetically Engineered Mouse Models, GDA:Genetically Engineered Mouse-Derived Allografts, CTC-GDA: CTC-Derived GDA

    Publish: 2019/06/12

  • Recombinant Antibodies for Cancer Therapy

    Mechanistic Overview of Antibody-Mediated Cancer Therapy

    Publish: 2019/06/13

  • Single-Cell Molecular Profiling for Precision Cancer Research

    Single-Cell Applications

    Publish: 2019/06/12

  • Small Molecules: Probing the role of immunometabolic reprogramming

    (1) Glycolysis (2) Fatty acid oxidation (3)Fatty acid synthesis (4)Glutaminolysis (5) TCA cycle (6) OXPHOS (7) Mitochondrial reactive oxygen species

    Publish: 2019/06/12

  • Systemic Communication in Tumor Microenvironment

    Together with chemokines, the tumour microenvironment that incorporates tumour cell characterization, immune cell profiling and tumor vasculature remodeling provides a complete picture to monitor tumor progression.

    Publish: 2019/06/12

  • T Cell Immunometabolism

    Interconnected metabolic pathways

    Publish: 2019/06/12

  • Therapeutic Challenge & Heterogeneity Tackling

    Distinct subclones exist within the tumor and response to treatments differently.

    Publish: 2019/06/12

  • TNF-TRAF signaling

    TNF-TRAF Signaling Pathway

    Publish: 2019/06/13

  • TNF-TRAF signaling

    TNFRSF Members and Their Adaptors

    Publish: 2019/06/13

  • Transcriptional Cyclin-Dependent Kinase

    Kinase inhibitors target CDKs in the basal transcriptional machinery could preferentially affect highly proliferative tumor cells.

    Publish: 2019/07/04

  • Treatment of IDH1/2-Mutated Cancers

    FDA Approval of First-In-Class Inhibitors for the Treatment of IDH1/2-Mutated Cancers

    Publish: 2019/06/10

  • Treatments Received FDA Approval for Cancers with BRAF V600E Mutation

    Treatments Received FDA Approval for Cancers with BRAF V600E Mutation

    Publish: 2019/06/12

  • TREM2 Signaling Pathway in CNS Microglia

    Upon ligand binding, the TREM2-associated DAP12 or DAP10 is tyrosine phosphorylated and recruits the SYK to phosphorylate the LAT1 or LAT2, which associate downstream mediators and adaptors, including PLCγ, P85, VAV1, GRB2 and SOS family. These pathways lead to Ca2+ mobilization, activation of the RAS–ERK pathway, PI3K–AKT pathway and actin remodeling involved in endocytosis, motility, phagocytosis, survival, proliferation, and differentiation related mechanisms.

    Publish: 2019/06/17

  • Tumor-Associated Antigens of CAR T Cell therapy

    Tumor-Associated Antigens of CAR T Cell therapy CAR T Cell therapy in Lung Cancer, Breast Cancer, Pancreatic Cancer, Melanoma, Glioma, Leukemia, Ovarian Cancer, Prostate Cancer, Liver Cancer, Gastric Cancer, Colorectal Cancer, Renal Cancer, Fallopian Tube Cancer, Endometrial Cancer, Cervical Cancer, Peritoneal Cancer, Neuroblastoma, Mesothelioma, Sarcoma, Osteosarcoma, Adenocarcinoma, Epithelial Carcinoma and Cholangiocarcinoma.

    Publish: 2019/06/10

  • Type I Diabetes Pathway

    Type I Diabetes Pathway

    Publish: 2019/06/13

  • Type II Diabetes Pathway

    Type II Diabetes Pathway

    Publish: 2019/06/13

  • Ubiquitin Mediated Proteasome Degradation

    Ubiquitin Mediated Proteasome Degradation

    Publish: 2019/06/13

  • Wnt/β-catenin Signaling Pathway

    Wnt/β-catenin Signaling Pathway

    Publish: 2019/06/13

  • Working Models of NLRP3 Activation

    NLRP3 activation can occur through both potassium-dependent and potassium-independent mechanisms. Potassium-dependent mechanisms depend on potassium efflux upon MLKL activation, opening of P2X7 channel or exposure to pore-forming toxins. Potassium-independent activation is mediated through metabolic perturbation.

    Publish: 2019/06/11

Back to Top

  • RSS
  • YouTube
  • Linkedin
  • Facebook